title: Role of probiotics in prevention of Candida infection in critically ill children.
abstract: Candidiasis accounts for 10-20% of bloodstream infections in paediatric intensive care units (PICUs) and a significant increase in morbidity, mortality, and length of hospital stay. Enteric colonisation by Candida species is one of the most important risk factor for invasive candidiasis. The local defence mechanisms may be altered in critically ill patients, thus facilitating Candida overgrowth and candidiasis. Systemic antifungals have been proven to be effective in reducing fungal colonisation and invasive fungal infections, but their use is not without harms. Early restoration or maintenance of intestinal microbial flora using probiotics could be one of the important tools for reducing Candida infection. A few studies have demonstrated that probiotics are able to prevent Candida growth and colonisation in neonates, whereas their role in preventing invasive candidiasis in such patients is still unclear. Moreover, there are no published data on role of probiotics supplementation in the prevention of candidiasis in critically ill children beyond neonatal period. There are gap in our knowledge regarding efficacy, cost effectiveness, risk-benefit potential, optimum dose, frequency and duration of treatment of probiotics in prevention of fungal infections in critically ill children. Studies exploring and evaluating the role of probiotics in prevention of Candida infection in critically ill children are needed.
authors.affiliation: Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
authors.forename: Suresh
authors.initials: S
authors.lastname: Kumar
authors.forename: Sunit
authors.initials: S
authors.lastname: Singhi
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage; D002176:Candida albicans / Q000187:drug effects; D058365:Candidiasis, Invasive / Q000382:microbiology / Q000517:prevention & control*; D002648:Child; D016638:Critical Illness / Q000628:therapy; D016469:Fungemia / Q000382:microbiology / Q000517:prevention & control; D041981:Gastrointestinal Tract / Q000382:microbiology; D006801:Humans; D015278:Intensive Care Units, Pediatric; D007778:Lactobacillus / Q000254:growth & development; D019936:Probiotics / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents